Literature DB >> 17950888

Intensity-modulated radiation therapy and helical tomotherapy: its origin, benefits, and potential applications in veterinary medicine.

Jessica A Lawrence1, Lisa J Forrest.   

Abstract

Intensity-modulated radiation therapy (IMRT), especially image-guided IMRT as represented by helical tomotherapy, is a novel approach to therapy and is rapidly evolving. Both of these forms of therapy aim to allow targeted radiation delivery to the tumor volume while minimizing dose to the surrounding normal tissues. Adaptive radiation therapy and conformal avoidance are possible with intensity-modulated therapy and helical tomotherapy, which offer opportunities for improved local tumor control, decreased normal tissue toxicity, and improved survival and quality of life. Human and veterinary patients are likely to benefit from the continued development of this radiation delivery technique, and data over the next several years should be crucial in determining its true benefit.

Entities:  

Mesh:

Year:  2007        PMID: 17950888     DOI: 10.1016/j.cvsm.2007.06.006

Source DB:  PubMed          Journal:  Vet Clin North Am Small Anim Pract        ISSN: 0195-5616            Impact factor:   2.093


  4 in total

1.  Stereotactic radiation therapy in veterinary medicine.

Authors:  Rachel Bloomfield
Journal:  Can Vet J       Date:  2015-01       Impact factor: 1.008

2.  Guiding the optimal translation of new cancer treatments from canine to human cancer patients.

Authors:  Chand Khanna; Cheryl London; David Vail; Christina Mazcko; Steven Hirschfeld
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

3.  Helical tomotherapy for single and multiple liver tumours.

Authors:  Tsair-Fwu Lee; Pei-Ju Chao; Fu-Min Fang; Te-Jen Su; Stephen W Leung; Hsuan-Chih Hsu
Journal:  Radiat Oncol       Date:  2010-06-24       Impact factor: 3.481

Review 4.  Ocular and periocular radiation toxicity in dogs treated for sinonasal tumors: A critical review.

Authors:  Friederike Wolf; Valeria S Meier; Simon A Pot; Carla Rohrer Bley
Journal:  Vet Ophthalmol       Date:  2020-04-12       Impact factor: 1.644

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.